Evotec 将来の成長

Future 基準チェック /46

Evotec利益と収益がそれぞれ年間74.9%と12.1%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に4.3% 76.1%なると予測されています。

主要情報

74.9%

収益成長率

76.1%

EPS成長率

Life Sciences 収益成長	18.8%
収益成長率	12.1%
将来の株主資本利益率	4.3%
アナリストカバレッジ	Good
最終更新日	18 Nov 2024

今後の成長に関する最新情報

Recent updates

Evotec stock dips despite US DoD contract up to $49.9M to develop antibody for plague

Sep 20

Evotec to acquire Central Glass Germany to bolster drug substance manufacturing

Aug 25

Evotec stock falls amid pact with Alpine for commercial process for potential lupus drug ALPN-303

Aug 10

Boehringer, Evotec, bioMérieux form joint venture Aurobac to combat antimicrobial resistance

Jul 06

業績と収益の成長予測

NasdaqGS:EVO - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,026	10	58	145	10
12/31/2025	905	-38	-1	77	10
12/31/2024	806	-145	-241	-49	10
9/30/2024	777	-171	-209	-36	N/A
6/30/2024	788	-171	-246	-55	N/A
3/31/2024	777	-91	-224	-12	N/A
12/31/2023	781	-84	-180	36	N/A
9/30/2023	821	-95	-188	-14	N/A
6/30/2023	798	-103	-246	-42	N/A
3/31/2023	800	-116	-39	143	N/A
12/31/2022	751	-176	24	206	N/A
9/30/2022	698	-180	121	297	N/A
6/30/2022	684	2	194	322	N/A
3/31/2022	650	90	58	183	N/A
12/31/2021	618	216	3	122	N/A
9/30/2021	571	247	-58	86	N/A
6/30/2021	541	112	-50	93	N/A
3/31/2021	515	42	-99	20	N/A
12/31/2020	501	6	-54	45	N/A
9/30/2020	485	14	-4	62	N/A
6/30/2020	470	35	0	46	N/A
3/31/2020	462	42	43	82	N/A
12/31/2019	446	38	10	42	N/A
9/30/2019	419	61	1	29	N/A
6/30/2019	404	77	46	74	N/A
3/31/2019	398	94	109	139	N/A
12/31/2018	375	84	128	156	N/A
9/30/2018	370	63	109	135	N/A
6/30/2018	338	31	N/A	80	N/A
3/31/2018	294	20	N/A	19	N/A
12/31/2017	264	23	N/A	11	N/A
9/30/2017	215	28	N/A	64	N/A
6/30/2017	193	35	N/A	73	N/A
3/31/2017	178	36	N/A	74	N/A
12/31/2016	165	28	N/A	67	N/A
9/30/2016	160	18	N/A	5	N/A
6/30/2016	148	6	N/A	-6	N/A
3/31/2016	144	17	N/A	-2	N/A
12/31/2015	128	17	N/A	16	N/A
9/30/2015	119	12	N/A	19	N/A
6/30/2015	104	11	N/A	23	N/A
3/31/2015	93	-4	N/A	9	N/A
12/31/2014	89	-7	N/A	-4	N/A
9/30/2014	85	-29	N/A	6	N/A
6/30/2014	89	-25	N/A	2	N/A
3/31/2014	86	-27	N/A	1	N/A
12/31/2013	86	-25	N/A	7	N/A

アナリストによる今後の成長予測

収入対貯蓄率: EVOは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: EVO今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: EVO今後 3 年以内に収益を上げることが予想されます。

収益対市場: EVOの収益 ( 12.1% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: EVOの収益 ( 12.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EVOの自己資本利益率は、3年後には低くなると予測されています ( 4.3 %)。

Evotec 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Evotec SE Updates Earnings Guidance for the Fiscal Year 2024

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Evotec SE Revises Revenue Guidance for the Full Year 2022

Recent updates

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisition of Evotec SE (XTRA:EVT).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisition of Evotec SE (XTRA:EVT).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisitionn of Evotec SE (XTRA:EVT).

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) made a non-binding expression of interest to acquire Evotec SE (XTRA:EVT) for €2 billion.

Triton Reportedly Weighs Takeover Deal for Drug Developer Evotec

Monacum Partners GmbH acquired Evotec Drug Substance (Germany) GmbH from Evotec SE (XTRA:EVT).

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Evotec: Weak Performance, But Long-Term Potential Is There

Evotec SE Updates Earnings Guidance for the Fiscal Year 2024

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE to Report Nine Months, 2024 Results on Nov 08, 2024

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE announced delayed 20-F filing

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec: Still A Speculative Buy After A Significant Decline

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Evotec SE Announces CEO Transition

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec SE, Annual General Meeting, Jun 20, 2023

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Amgen joins TIAP, Evotec at innovation hub for forming life science companies

Evotec stock dips despite US DoD contract up to $49.9M to develop antibody for plague

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Evotec to acquire Central Glass Germany to bolster drug substance manufacturing

Evotec SE Revises Revenue Guidance for the Full Year 2022

Evotec stock falls amid pact with Alpine for commercial process for potential lupus drug ALPN-303

Evotec SE (XTRA:EVT) completed the acquisition of Rigenerand S.R.L. from Xyence Capital SGR and others.

Boehringer, Evotec, bioMérieux form joint venture Aurobac to combat antimicrobial resistance

Evotec Se Appoints Camilla Macapili Languille as New Member of Supervisory Board

Evotec SE (XTRA:EVT) agreed to acquire Rigenerand S.R.L. for €25 million.

Evotec SE Confirms Revenue Guidance for 2022

Evotec Se Provides Revenue Guidance for 2022

Evotec SE Announces That the Company Has Been Informed by Bayer About A Decision to Discontinue the Development of the Investigational P2X3 Receptor Antagonist Eliapixant

Evotec SE to Report Q1, 2022 Results on May 11, 2022

Evotec Receives € 7.5 Million Grant for Development of Covid-19 Therapeutic from German Federal Ministry of Education and Research

Evotec SE Provides Revenue Guidance for the Full Year of 2021

Evotec SE (XTRA:EVT) acquired Campus Levi-Montalcini from GlaxoSmithKline plc (LSE:GSK).

Evotec SE Reports Revenue Guidance for Revenue for the Full-Year 2021

Evotec SE Launches 'beLAB1407' to Accelerate Translational Research from the UK's Academic Life Science Ecosystem in Collaboration with Bristol Myers Squibb

Evotec SE Provides Earnings Guidance for the Year 2021

Chinook Therapeutics, Inc. and Evotec SE Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases

Evotec and Related Sciences Enter Integrated Drug Discovery and Development Partnership

Evotec SE Enters into Multi-Year Partnership with the Medical Center Hamburg-Eppendorf

Evotec Appoints Cord Dohrmann to the German Council of Science and Humanities

Evotec Starts Clinical Development of Chikungunya Antibody together with NIAID and Leading Academic Research Organisation

Evotec SE to Report Q3, 2021 Results on Nov 11, 2021

Evotec SE Receives USD 6 Million Payment from Bristol Myers Squibb Company

Evotec SE Partners with Alloy Therapeutics to Expand Its Antibody Discovery Platform

Evotec and Rappta Therapeutics Enter Discovery and Development Partnership Focused on Oncology Target

Evotec SE announced that it expects to receive €249.999996 million in funding from Mubadala Investment Company PJSC, Novo Holdings A/S

Evotec Achieves Milestone in Its Neurodegeneration Collaboration with Bristol Myers Squibb

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘